News

Investigational Extended-Release Ralinepag for PAH Treatment Shows Favorable Results in Phase 1 Trials

Extended-release tablets of ralinepag, Arena Pharmaceuticals’ treatment candidate for pulmonary arterial hypertension (PAH), show a superior pharmacokinetic profile over both immediate-release ralinepeg capsules and approved immediate-release medication Uptravi (selexipag), according to two Phase 1 trials in healthy volunteers. Pharmacokinetics (PK) refer to how a drug is absorbed,…

Higher Concentration of Inhaled Ventavis May Help PAH Patients Stick to Treatment, Study Suggests

More pulmonary arterial hypertension (PAH) patients were able to achieve complete daily inhalations after switching to a more concentrated formulation of Ventavis (iloprost), which also reduced the duration of each treatment administration, an observational study reports. The study looked at the inhalation behavior of PAH patients who were switched from…

Treatment with Milrinone Improves Heart Function in Patients with PH Due to Left Heart Disease, Study Finds

Intravenous treatment with the approved heart failure medicine milrinone leads to significant improvements in heart structure and function in patients with mild-to-moderate pulmonary hypertension (PH) due to left heart disease, a study has found.” The report titled “Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients…